Butylphthalide
Based on 12 publication(s) in Google Scholar
Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.98%
- No. CAS: 6066-49-5
- Fòrmula: C12H14O2
- Peso molecular:190.24
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0099
Edaravone -
HY-16561
Resveratrol -
HY-N0401A
(Z)-Ligustilide -
HY-N0336
3-Butylidenephthalide -
HY-N0303
Idebenone -
HY-10585A
Valproic acid sodium -
HY-K0010
Protease Inhibitor Cocktail (EDTA-Free, 100× in DMSO) -
HY-B0647R
Butylphthalide (Standard) -
HY-122778
δ-Tocotrienol -
HY-N0188
Esculin -
HY-B0558
Carbimazole -
HY-12511
SKF-86002
Publications Citing Use of MedChemExpress (MCE) Butylphthalide
More- J Adv Res. 2025 Dec 7:S2090-1232(25)00964-6. [Abstract]
- J Adv Res. 2025 Jun:72:369-385. [Abstract]
- Phytomedicine. 2026 Jun:155:158069. [Abstract]
- CNS Neurosci Ther. 2026 Jun;32(6):e70948. [Abstract]
- Mol Neurobiol. 2026 Jan 16;63(1):369. [Abstract]
- Front Pharmacol. 2024 Feb 23:15:1347241. [Abstract]
- Front Aging Neurosci. 2019 Feb 28:11:44. [Abstract]
- World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
- Food Sci Nutr. 2026 Mar 10;14(3):e71495. [Abstract]
- Front Biosci (Landmark Ed). 2025 Dec 15;30(12):46724. [Abstract]
- Chem Biol Drug Des. 2025 Oct;106(4):e70180. [Abstract]
- Oxid Med Cell Longev. 2022 Jul 20:2022:9468040. [Abstract]
Customer Validation & Images
-
Histological Imaging/Staining
-
IF
-
Cell Migration/Invasion Assay
-
Apoptosis Analysis
-
WB
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
>1 mM
Compound: NBP
|
Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
|
[PMID: 22827516] |
| Platelet | IC50 |
0.48 mM
Compound: NBP
|
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
|
[PMID: 22827516] |
| Platelet | IC50 |
0.74 mM
Compound: NBP
|
Antiplatelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 5 mins followed by addition of ADP measured within 5 mins by Borns turbidimetric method
Antiplatelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 5 mins followed by addition of ADP measured within 5 mins by Borns turbidimetric method
|
[PMID: 27031213] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Old male SAMP8 mice and SAMR1 mice[3]
-
Dosage:40 mg/kg, 80 mg/kg, 160 mg/kg
-
Administration:Orally daily, 60 days
-
Result:Shorted escape latency time on day 7.
Improved SAMP8 mice learning deficits.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 6066-49-5
-
Appearance Liquid (Density: 1.0527 g/cm3)
-
Peso molecular 190.24
-
Fòrmula C12H14O2
-
Color Colorless to light yellow
-
SMILES
O=C1OC(CCCC)C2=C1C=CC=C2
-
Synonyms
3-n-Butylphthalide; 3-Butylphthalide
-
Structure Classification
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Butylphthalide enhances neurorestoration following ischemic stroke by restructuring microvasculature through vimentin modulation. [Abstract]2025 Dec 7:S2090-1232(25)00964-6. PMID: 41365434 -
J Adv Res
2025 Jun:72:369-385. PMID: 38972542 -
Phytomedicine
Huang-Qi-Long-Dan Granule alleviates ischemic stroke injury by regulating the crosstalk between Nrf2 and NF-κB signaling. [Abstract]2026 Jun:155:158069. PMID: 41861685 -
CNS Neurosci Ther
DL-3-n-Butylphthalide Protects Against PrP106 -126-Induced Neurotoxicity Through NRF2 Signaling and OPA1/DRP1-Mediated Mitochondrial Dynamics. [Abstract]2026 Jun;32(6):e70948. PMID: 42228054 -
Mol Neurobiol
3-n-Butylphthalide Protects SH-SY5Y Cells from Ferroptosis by Inhibiting ACSL4-Mediated Lipid Peroxidation. [Abstract]2026 Jan 16;63(1):369. PMID: 41545774 -
Front Pharmacol
Unveiling the potential of Butylphthalide: inhibiting osteoclastogenesis and preventing bone loss. [Abstract]2024 Feb 23:15:1347241. PMID: 38464734 -
Front Aging Neurosci
Dl-3- n-Butylphthalide Exerts Dopaminergic Neuroprotection Through Inhibition of Neuroinflammation. [Abstract]2019 Feb 28:11:44. PMID: 30873019
Butylphthalide purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2019 Feb 28:11:44. [Abstract]
The protein level of TNF-α, IL-1β, iNOS and COX2 is analyzed by Western Blot with or without the treatment of Butylphthalide (NBP) and LPS.
-
World J Diabetes
Dl-3-n-butylphthalide ameliorates diabetic foot ulcer by inhibiting apoptosis and promoting angiogenesis. [Abstract]2025 Apr 15;16(4):101916. PMID: 40236845
Butylphthalide purchased from MedChemExpress. Usage Cited in: World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
The HE and Masson’s trichrome staining results showed that the Butylphthalide (NBP) (10 μM) group significantly increased neovascularization and fibroblast proliferation relative to the model group.
Butylphthalide purchased from MedChemExpress. Usage Cited in: World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
Immunofluorescence results demonstrated higher expressions of Ki67 and CD31 in the Butylphthalide (NBP) (10 μM) group than in the model group.
Butylphthalide purchased from MedChemExpress. Usage Cited in: World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
Butylphthalide (NBP) (15 μM) treatment significantly enhanced the proliferation of HUVEC and HDF cells under HG conditions.
Butylphthalide purchased from MedChemExpress. Usage Cited in: World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
The flow cytometry detection results showed that, compared to the HG group, the apoptosis rate in the Butylphthalide (NBP) (15 μM) + HG group was markedly reduced in HUVEC, HaCaT, and HDF cells.
Butylphthalide purchased from MedChemExpress. Usage Cited in: World J Diabetes. 2025 Apr 15;16(4):101916. [Abstract]
Butylphthalide (NBP) (15 μM) activated the AGE-RAGE signaling pathway and modulated the biological functions of HUVEC, HaCaT, and HDF cells, to treat DFU by Western blot.
-
Food Sci Nutr
Traditional Chinese Herbal Formula XuMingZhuSan Alleviates Neuronal Ferroptosis in Rats After Stroke by Activating the NRF2/GPX4/SLC7A11 Pathway. [Abstract]2026 Mar 10;14(3):e71495. PMID: 41822239 -
Front Biosci (Landmark Ed)
Ginkgolide B Promotes Angiogenesis After Oxygen-Glucose Deprivation by Regulating AKT1 in bEnd.3 Cells. [Abstract]2025 Dec 15;30(12):46724. PMID: 41504064 -
Chem Biol Drug Des
Dl-3-n-Butylphthalide Inhibits Autophagy to Alleviate the Neuronal Apoptosis After Spinal Cord Injury by Elevating YAP via Inactivating the Hippo Signaling Pathway. [Abstract]2025 Oct;106(4):e70180. PMID: 41104600 -
Oxid Med Cell Longev
DL-3-N-Butylphthalide Promotes Cartilage Extracellular Matrix Synthesis and Inhibits Osteoarthritis Development by Regulating FoxO3a. [Abstract]2022 Jul 20:2022:9468040. PMID: 35910845
Solvente y solubilidad
In Vitro:
DMSO : 250 mg/mL (1314.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (10.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (10.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 13.33 mg/mL (70.07 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Cui LY, et al. Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial. Chin Med J (Engl). 2013;126(18):3405-10. [Content Brief]
[2]. Zhao W, et al. 3-N-butylphthalide improves neuronal morphology after chronic cerebral ischemia. Neural Regen Res. 2014 Apr 1;9(7):719-26. [Content Brief]
[3]. Wang X, et al. Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. Org Biomol Chem. 2014 Aug 21;12(31):5995-6004. [Content Brief]
[4]. Wang F, et al. Improvement of cognitive deficits in SAMP8 mice by 3-n-butylphthalide. Neurol Res. 2014 Mar;36(3):224-33. [Content Brief]
[5]. Chen XQ, Qiu K, Liu H, He Q, Bai JH, Lu W. Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin Med J (Engl). 2019;132(12):1467-1477. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.2565 mL | 26.2823 mL | 52.5646 mL | 131.4116 mL |
| 5 mM | 1.0513 mL | 5.2565 mL | 10.5129 mL | 26.2823 mL | |
| 10 mM | 0.5256 mL | 2.6282 mL | 5.2565 mL | 13.1412 mL | |
| 15 mM | 0.3504 mL | 1.7522 mL | 3.5043 mL | 8.7608 mL | |
| 20 mM | 0.2628 mL | 1.3141 mL | 2.6282 mL | 6.5706 mL | |
| 25 mM | 0.2103 mL | 1.0513 mL | 2.1026 mL | 5.2565 mL | |
| 30 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | 4.3804 mL | |
| 40 mM | 0.1314 mL | 0.6571 mL | 1.3141 mL | 3.2853 mL | |
| 50 mM | 0.1051 mL | 0.5256 mL | 1.0513 mL | 2.6282 mL | |
| 60 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 80 mM | 0.0657 mL | 0.3285 mL | 0.6571 mL | 1.6426 mL | |
| 100 mM | 0.0526 mL | 0.2628 mL | 0.5256 mL | 1.3141 mL |
Butylphthalide Related Classifications
HY-B0647 Related Classifications
Powered by Bioz